CGEM Q3 2023 Earnings — Cullinan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CGEMCullinan Therapeutics, Inc.

$894M

Q3 2023 Earnings

Healthcare Medical - Pharmaceuticals

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$45M

Net Income

-$39M

EPS (Diluted)

$-0.92

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$495M

Total Liabilities

$26M

Stockholders' Equity

$469M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$45M	-$30M	-52.0%
Net Income	-$39M	-$25M	-58.0%